Augmentin Dosing for Community-Acquired Pneumonia in Adults
For hospitalized adults with community-acquired pneumonia, use high-dose amoxicillin-clavulanate 2000/125 mg twice daily orally, or intravenous amoxicillin-clavulanate 2 g every 6 hours for severe cases requiring ICU admission with aspiration risk or lung abscess.
Oral Regimens for Non-ICU Hospitalized Patients
Standard dosing: The pharmacokinetically enhanced formulation of amoxicillin-clavulanate 2000/125 mg twice daily is superior to conventional dosing for CAP 1. This high-dose regimen achieves adequate coverage against penicillin-resistant Streptococcus pneumoniae with MICs up to 4 mcg/mL 1, 2.
- Dose: 2000/125 mg orally twice daily
- Duration: 7 days minimum 1
- Administration: Take at the start of meals to minimize GI intolerance and enhance clavulanate absorption 3
Critical caveat: Amoxicillin-clavulanate should always be combined with a macrolide (azithromycin 500 mg day 1, then 250 mg daily, or clarithromycin 500 mg twice daily) for hospitalized CAP patients 1. Combination therapy with a beta-lactam plus macrolide reduces mortality compared to beta-lactam monotherapy 1.
Alternative oral regimen if high-dose formulation unavailable:
- Amoxicillin-clavulanate 875/125 mg three times daily 4
- Still requires macrolide combination
Intravenous Regimens for ICU Patients
For severe CAP requiring ICU admission:
When aspiration pneumonia, lung abscess, or cavitated pneumonia is suspected:
- IV amoxicillin-clavulanate 2 g every 6 hours 4
- Must be combined with either azithromycin (level II evidence) or a respiratory fluoroquinolone (level I evidence) 5
For standard severe CAP without aspiration risk: Amoxicillin-clavulanate is not the preferred beta-lactam. Use ceftriaxone, cefotaxime, or ampicillin-sulbactam instead 5.
Renal Dose Adjustments
The evidence does not provide specific renal dosing for adults, but critical considerations include:
Patients on renal replacement therapy: Amoxicillin-clavulanate clearance is significantly increased by RRT, even with normal native kidney function 6. Consider 2.2 g every 6-8 hours with therapeutic drug monitoring in ICU patients on RRT 6.
Standard renal impairment: Dose with caution and monitor hepatic function regularly 3. The clavulanate component is primarily renally cleared.
Contraindications and Alternatives
If penicillin allergy:
- Use a respiratory fluoroquinolone (levofloxacin 750 mg daily or moxifloxacin 400 mg daily) 5, 7
- For ICU patients: respiratory fluoroquinolone plus aztreonam 5
If treatment failure or macrolide resistance >25%:
- Switch to respiratory fluoroquinolone monotherapy 7
- Consider ceftriaxone 1-2 g daily plus macrolide 4
If prior antibiotic use within 3 months:
- Amoxicillin-clavulanate resistance increases significantly with recent antibiotic exposure 8
- Consider alternative regimen (respiratory fluoroquinolone or ceftriaxone-based therapy)
Duration of Therapy
- Minimum 5 days if afebrile for 48-72 hours with clinical stability 5
- Standard duration: 7 days for uncomplicated CAP 1, 2
- 3 days may suffice if clinical stability achieved by day 3 in younger patients with few comorbidities 9
- Longer duration (10-14 days) only if complicated by extrapulmonary infection or inadequate initial coverage 5
Key Clinical Pitfalls
Never use amoxicillin-clavulanate as monotherapy for hospitalized CAP—mortality benefit only demonstrated with macrolide combination 1
Do not substitute standard-dose formulations (875/125 mg) for high-dose (2000/125 mg) when treating suspected resistant pneumococcus 3, 2
Hepatic monitoring required in all patients, particularly those with hepatic impairment 3
Recent antibiotic exposure is the strongest predictor of resistance—choose alternative if antibiotics used within 3 months 8